Gates Foundation to invest up to US$40m in UK immunotherapy firm Immunocore
[LONDON] The Bill & Melinda Gates Foundation is to invest up to US$40 million in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.
Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it has collaborations with Roche, GlaxoSmithKline, AstraZeneca and Eli Lilly.
The tie-up with the Gates Foundation will extend the work into finding and developing new treatments for tuberculosis, HIV and other infectious diseases.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action